{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:18:06Z","timestamp":1780604286380,"version":"3.54.1"},"reference-count":21,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2004,6,4]],"date-time":"2004-06-04T00:00:00Z","timestamp":1086307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Allergy"],"published-print":{"date-parts":[[2004,7]]},"abstract":"<jats:p><jats:bold>Background:\u2002<\/jats:bold>The aim of this study is to establish the efficacy and safety of rupatadine<jats:italic>vs<\/jats:italic>ebastine and placebo in the treatment of seasonal allergic rhinitis (SAR). Rupatadine is a new second generation H<jats:sub>1<\/jats:sub>\u2010antihistamine with once\u2010daily dosing that may provide better control of symptoms than the currently used H<jats:sub>1<\/jats:sub>\u2010receptor blockers because of its dual pharmacological profile (anti\u2010PAF and anti\u2010H<jats:sub>1<\/jats:sub>).<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold>In a multicentre study, 250 patients with SAR were included in a double\u2010blind, randomized, parallel\u2010group and placebo\u2010controlled study. Patients received either rupatadine 10\u2003mg, ebastine 10\u2003mg or placebo once daily for 2\u2003weeks. The main efficacy outcome was based on the patient's record of severity of nasal symptoms (sneezing, nasal itching, runny nose and nasal obstruction) and nonnasal symptoms (conjunctival itching, tearing and pharyngeal itching). The daily total symptom score (DTSS) was the mean of the DSS recorded for each of the seven symptoms assessed, and the mean DTSS (mDTSS) was the mean of the DTSS values for each study day.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold>Significant differences in mDTSS were detected between rupatadine and placebo (33% lower for rupatadine group;<jats:italic>P<\/jats:italic>\u2003=\u20030.005) after 2\u2003weeks of treatment. The TSS for rupatadine were 22% lower than for ebastine, although the differences were not statistically significant. No serious adverse events were reported during the study period.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold>Rupatadine 10\u2003mg once daily was clearly superior to placebo in alleviating the symptoms of SAR over a 2\u2010week period. In comparison with ebastine, rupatadine shows a trend towards a better profile as regard several secondary efficacy variables.<\/jats:p>","DOI":"10.1111\/j.1398-9995.2004.00576.x","type":"journal-article","created":{"date-parts":[[2004,6,4]],"date-time":"2004-06-04T08:26:32Z","timestamp":1086337592000},"page":"766-771","source":"Crossref","is-referenced-by-count":46,"title":["Rupatadine 10\u2003mg and ebastine 10\u2003mg in seasonal allergic rhinitis: a comparison study"],"prefix":"10.1111","volume":"59","author":[{"given":"E. M.","family":"Guada\u00f1o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Serra\u2010Batlles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Meseguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"De Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Valero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Picado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Rupatadine Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,6,4]]},"reference":[{"key":"e_1_2_14_2_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2002.23625.x"},{"key":"e_1_2_14_3_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2003.00054.x"},{"key":"e_1_2_14_4_2","first-page":"666","article-title":"The clinical safety of H1\u2010receptor antagonists. An EAACI position paper","volume":"51","author":"Passalacqua G","year":"1996","journal-title":"Allergy"},{"key":"e_1_2_14_5_2","first-page":"149","article-title":"Epidemiology of allergic rhinitis","volume":"106","author":"Mygind N","year":"1996","journal-title":"Pediatr Allergy Immunol"},{"key":"e_1_2_14_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(87)90286-7"},{"key":"e_1_2_14_7_2","first-page":"114","article-title":"Rupatadine, a new potent, orally active dual antagonist of histamine and platelet\u2010activating factor (PAF)","volume":"280","author":"Merlos M","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_14_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/PL00000216"},{"key":"e_1_2_14_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2299(199806\/07)44:2\/3<49::AID-DDR1>3.0.CO;2-A"},{"issue":"63","key":"e_1_2_14_10_2","first-page":"275","article-title":"A dose ranging study of rupatadine fumarate in patients with seasonal allergic rhinitis","volume":"55","author":"Izquierdo I","year":"2000","journal-title":"Allergy"},{"issue":"68","key":"e_1_2_14_11_2","first-page":"200","article-title":"Rupatadine exhibits a better profile than ebastine in patients with seasonal allergic rhinitis","volume":"56","author":"Izquierdo I","year":"2001","journal-title":"Allergy"},{"key":"e_1_2_14_12_2","volume-title":"Adverse reaction terminology","author":"The Uppsala Monitoring Center","year":"1998"},{"key":"e_1_2_14_13_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200059040-00018"},{"key":"e_1_2_14_14_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2000.105525"},{"issue":"4","key":"e_1_2_14_15_2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1399-3038.1993.tb00339.x","article-title":"A placebo\u2010controlled trial of cetirizine in seasonal allergic rhino\u2010conjunctivitis in children aged 6 to 12\u2003years","volume":"4","author":"Masi M","year":"1993","journal-title":"Pediatr Allergy Immunol"},{"key":"e_1_2_14_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000237289"},{"key":"e_1_2_14_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)63269-3"},{"issue":"57","key":"e_1_2_14_18_2","first-page":"245","article-title":"Rupatadine in allergic rhinitis: pooled analysis of efficacy data","volume":"57","author":"Perez I","year":"2002","journal-title":"Allergy"},{"key":"e_1_2_14_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(95)70001-3"},{"key":"e_1_2_14_20_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-199816060-00001"},{"key":"e_1_2_14_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1996.tb04490.x"},{"issue":"63","key":"e_1_2_14_22_2","first-page":"275","article-title":"Central and peripheral CNS evaluation of rupatadine fumarate: a new H1\u2010antihistamine and PAF antagonist","volume":"55","author":"Lurigados C","year":"2000","journal-title":"Allergy"}],"container-title":["Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1398-9995.2004.00576.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1398-9995.2004.00576.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T15:31:43Z","timestamp":1705159903000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1398-9995.2004.00576.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6,4]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["10.1111\/j.1398-9995.2004.00576.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1398-9995.2004.00576.x","archive":["Portico"],"relation":{},"ISSN":["0105-4538","1398-9995"],"issn-type":[{"value":"0105-4538","type":"print"},{"value":"1398-9995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6,4]]}}}